XOMA Royalty Corporation announces cash dividends for Series A and B Preferred Stock, payable January 15, 2026.
Quiver AI Summary
XOMA Royalty Corporation announced that its Board of Directors has approved cash dividends for holders of its preferred stock. Shareholders of the 8.625% Series A Cumulative Perpetual Preferred Stock will receive $0.53906 per share, while holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock will get $0.52344 per depositary share. These dividends are set to be paid around January 15, 2026, for those on record by January 2, 2026. XOMA Royalty focuses on acquiring potential future economics from both pre-commercial and commercial therapeutic candidates, providing sellers with funding options to further their drug development efforts. The company has a diverse portfolio of assets related to various drug products in development.
Potential Positives
- Announcement of cash dividends for Series A and Series B Preferred Stock demonstrates a commitment to returning value to shareholders.
- The planned payment of dividends on January 15, 2026, indicates strong financial health and stability within the company.
- XOMA Royalty's role in providing non-dilutive funding to biotech companies supports innovation and growth in the pharmaceutical industry.
- The expansion of its portfolio with significant commercial assets underscores XOMA's strategic positioning in the biotech sector.
Potential Negatives
- The press release highlights the approval of cash dividends, which may raise concerns among investors about the company's cash flow and profitability, as dividends can be indicative of a company distributing cash rather than reinvesting in growth opportunities.
- The mention that "efficacy and safety have not been established" for investigational compounds may create uncertainty regarding the future success and viability of the company's pipeline, potentially affecting investor confidence.
- The reliance on a portfolio mostly composed of investigational compounds without guarantees of commercial availability may signal risks associated with the company's long-term revenue generation.
FAQ
What are the cash dividends announced by XOMA Royalty Corporation?
XOMA Royalty announced cash dividends of $0.53906 for Series A and $0.52344 for Series B Preferred Stock holders.
When will the dividends be paid?
The dividends will be paid on or about January 15, 2026, to holders of record as of January 2, 2026.
What is XOMA Royalty Corporation's business model?
XOMA Royalty aggregates biotechnology royalties, acquiring future economics from licensed therapeutic candidates to support biotech companies.
What types of products are in XOMA Royalty's portfolio?
The portfolio includes both commercial assets, like VABYSMO® and investigational compounds still in development.
Where can I find more information about XOMA Royalty?
More information can be found on XOMA Royalty's website, www.xoma.com, or by following them on LinkedIn.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$XOMA Insider Trading Activity
$XOMA insiders have traded $XOMA stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $XOMA stock by insiders over the last 6 months:
- OWEN HUGHES (Chief Executive Officer) purchased 100,000 shares for an estimated $2,505,000
- THOMAS M. BURNS (SVP, Finance & CFO) has made 0 purchases and 3 sales selling 4,330 shares for an estimated $155,820.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$XOMA Hedge Fund Activity
We have seen 37 institutional investors add shares of $XOMA stock to their portfolio, and 29 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MORGAN STANLEY added 102,029 shares (+6.6%) to their portfolio in Q3 2025, for an estimated $3,932,197
- EVERSEPT PARTNERS, LP removed 45,017 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $1,134,428
- STONEPINE CAPITAL MANAGEMENT, LLC removed 36,684 shares (-24.1%) from their portfolio in Q3 2025, for an estimated $1,413,801
- WELLINGTON MANAGEMENT GROUP LLP added 32,616 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,257,020
- WOODLINE PARTNERS LP added 29,715 shares (+16.5%) to their portfolio in Q3 2025, for an estimated $1,145,216
- VANGUARD GROUP INC added 29,298 shares (+4.6%) to their portfolio in Q3 2025, for an estimated $1,129,144
- JANE STREET GROUP, LLC added 27,363 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,054,570
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$XOMA Analyst Ratings
Wall Street analysts have issued reports on $XOMA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 12/11/2025
To track analyst ratings and price targets for $XOMA, check out Quiver Quantitative's $XOMA forecast page.
$XOMA Price Targets
Multiple analysts have issued price targets for $XOMA recently. We have seen 3 analysts offer price targets for $XOMA in the last 6 months, with a median target of $76.0.
Here are some recent targets:
- Joseph Pantginis from HC Wainwright & Co. set a target price of $97.0 on 12/11/2025
- David Risinger from Leerink Partners set a target price of $45.0 on 12/11/2025
- Elemer Piros from LUCID CAPITAL MARKETS set a target price of $76.0 on 12/09/2025
Full Release
EMERYVILLE, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced its Board of Directors has authorized the following cash dividends to holders of XOMA Royalty’s Series A and Series B Cumulative Preferred Stock:
Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share.
Holders of depositary shares, each representing 1/1000 of a share of XOMA Royalty’s 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO), shall receive a cash dividend equal to $0.52344 per depositary share.
The preferred dividends will be paid on or about January 15, 2026, to respective holders of record at the close of business on January 2, 2026.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the sellers receive non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. XOMA Royalty has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about XOMA Royalty and its portfolio, please visit
www.xoma.com
or follow XOMA Royalty Corporation on
LinkedIn
.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO ® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY ® [coagulation factor IX (recombinant)], and DSUVIA ® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available.
|
Investor Contact
Juliane Snowden XOMA Royalty Corporation +1 646-438-9754 [email protected] |
Media Contact
Kathy Vincent KV Consulting & Management [email protected] |
